Active, not recruitingPhase 2NCT06289998

Study of Tamibarotene in Patients With ADPKD

Studying Autosomal dominant polycystic kidney disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rege Nephro Co., Ltd.
Intervention
Tamibarotene(drug)
Enrollment
70 enrolled
Eligibility
26-55 years · All sexes
Timeline
20232025

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06289998 on ClinicalTrials.gov

Other trials for Autosomal dominant polycystic kidney disease

Additional recruiting or active studies for the same condition.

See all trials for Autosomal dominant polycystic kidney disease

← Back to all trials